• We collected and analyzed data from all acquired aplastic anemia patients who underwent a haploidentical transplantation with posttransplant cyclophosphamide in Europe from 2011 to 2017 (n = 33). (aamds.org)
  • Our results using unmanipulated haploidentical transplantation and posttransplant cyclophosphamide for treating refractory AA patients are encouraging, but warrant confirmation in a prospective study with a larger number of patients and longer follow-up. (aamds.org)
  • Cyclophosphamide is contraindicated in patients who have demonstrated a previous hypersensitivity to it. (nih.gov)
  • Eighteen patients with progressive pulmonary dysfunction, diminished vital capacity (VC), and/or decreased static lung compliance (Cst) were treated with cyclophosphamide and corticosteroids for 1 year. (nih.gov)
  • Cyclophosphamide may have a beneficial effect on pulmonary fibrosis in patients with SSc and elevated levels of acute-phase proteins. (nih.gov)
  • Controlled trials of cyclophosphamide in pulmonary SSc should be performed and should focus on such patients. (nih.gov)
  • Injected cyclophosphamide distributed rapidly into 64% of body weight, and plasma cyclophosphamide half-life in patients without prior drug exposure was 6.5 hr. (aacrjournals.org)
  • Cyclophosphamide is a antineoplastic , immunosuppressive agent that is FDA approved for the treatment of malignant diseases , minimal change nephrotic syndrome in pediatric patients. (wikidoc.org)
  • This multicenter, phase 2 trial evaluated the efficacy and safety of weekly oral pomalidomide-cyclophosphamide-dexamethasone (PCD) in patients with MM in first relapse after treatment with lenalidomide-bortezomib-dexamethasone (RVD). (bloodjournal.org)
  • The effect of pulse cyclophosphamide treatment was retrospectively assessed in 25 systemic lupus erythematosus (SLE) patients with central nervous system involvement. (nih.gov)
  • Cyclophosphamide was well tolerated in all patients with only minor side effects. (nih.gov)
  • Guillevin et al suggested that patients with a 5-factors score (FFS) of zero may be treated successfully with corticosteroids alone, with cyclophosphamide administered only as second-line treatment in cases of persistent disease, relapse, or inability to taper steroids. (medscape.com)
  • They recommend that, cyclophosphamide should be part of the initial regimen in combination with steroids in patients with an FFS of 1 or more. (medscape.com)
  • Therapy with steroids and cyclophosphamide places patients at high risk for infections. (medscape.com)
  • Unmanipulated haploidentical stem cell transplantation (haploSCT) with post-transplant cyclophosphamide is an option for patients with advanced hematologic malignancies. (bioportfolio.com)
  • Arm I: Patients receive doxorubicin IV over 15 minutes and cyclophosphamide IV over 15 minutes on day 1 followed by doxorubicin IV over 15 minutes, cyclophosphamide IV over 15 minutes, and docetaxel IV over 1 hour on day 22. (bioportfolio.com)
  • Intravenous (IV) cyclophosphamide (Cy) was more effective than IV methylprednisolone (MP) for patients with acute severe neuropsychiatric SLE expressing seizures, peripheral neuropathy, optic neuritis, and brainstem disease. (bmj.com)
  • The primary objective of this study: 1) Determine the best response rate (complete and partial response) achieved following therapy with bortezomib, cyclophosphamide, and rituximab in patients with relapsed/refractory aggressive diffuse and nodular mantle cell lymphoma (MCL) and its blastic variant. (mdanderson.org)
  • Adequate hydration is needed for patients receiving cyclophosphamide to reduce the risk of hemorrhagic cystitis. (ebscohost.com)
  • The authors evaluated the combination of etoposide/cyclophosphamide (VP/CY) as initial, presurgical therapy for patients with osteosarcoma and found an 88% response rate for the primary tumor and any metastases. (uni-bonn.de)
  • Determine the overall and progression-free survival of patients with B-cell prolymphocytic leukemia treated with immunochemotherapy comprising fludarabine, cyclophosphamide, and rituximab. (knowcancer.com)
  • Patients receive fludarabine IV and cyclophosphamide IV on days 1-3. (knowcancer.com)
  • Further evaluation of patients treated with cyclophosphamide and those without this treatment revealed a higher median FSH levels (6.4 vs. 4.6 IU/L, p=0.023). (biomedsearch.com)
  • In the study, reported in the December 15 issue of Cancer Research, blood samples from 12 patients who took cyclophosphamide were analyzed, using new methods that stabilized the metabolites and allowed them to be measured. (cancernetwork.com)
  • An all-oral triplet therapy of ixazomib (Ninlaro), cyclophosphamide, and dexamethasone demonstrated promising early response rates in elderly patients with newly diagnosed multiple myeloma, according to phase II data presented at the 2015 ASH Annual Meeting. (onclive.com)
  • Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma. (wiley.com)
  • PATIENTS AND METHODS: A total of 228 patients with stage III or IV FSCL or FML were randomized to cyclophosphamide or the combination of cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B). Treatment was continued in responders for 2 years beyond maximal response. (eviq.org.au)
  • CONCLUSION: There is no advantage to the initial use of the relatively intensive combination, CHOP-B, for patients with FSCL compared with the less toxic single agent, cyclophosphamide. (eviq.org.au)
  • We report the use of a risk-adapted oral regimen of cyclophosphamide, thalidomide, and dexamethasone (CTD) or attenuated CTD (CTDa) in 75 patients with advanced AL amyloidosis, including 44 patients with clonal relapse after prior therapy. (bloodjournal.org)
  • Unmanipulated stem cells and post-transplant cyclophosphamide were given to all patients as GVHD prophylaxis. (ovid.com)
  • This phase II trial studies how well eribulin mesylate works in combination with doxorubicin hydrochloride and cyclophosphamide in treating patients with human epidermal growth factor receptor 2 (HER2)-negative inflammatory breast cancer before surgery. (cancer.gov)
  • Giving eribulin mesylate together with doxorubicin hydrochloride and cyclophosphamide before surgery may be an effective treatment in HER2-negative inflammatory breast cancer patients. (cancer.gov)
  • To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis. (bmj.com)
  • 1- 3 Studies of patients with malignant diseases treated with cyclophosphamide have indicated an association between cyclophosphamide and the risk of bladder cancer 4, 5 based on less than 20 bladder cancers. (bmj.com)
  • Our present knowledge of bladder cancer risk in relation to cyclophosphamide use in Wegener's granulomatosis rests upon fewer than a dozen cancer cases detected in two limited series of selected patients treated with cyclophosphamide (n = 145 and n = 158, respectively). (bmj.com)
  • The aim of this study was to investigate the impact of the CYP2B6 SNPs G516T, A785G and C1459T, GSTP1 SNP Ile105Val, and GSTM1 and GSTT1 null variants, on the outcome for cyclophosphamide treated MM patients, in order to find markers of value for individualised therapy. (diva-portal.org)
  • We used allele specific PCR and Pyrosequencing to investigate the impact of CYP2B6 SNPs G516T, A785G and C1459T, GSTP1 Ile105Val, and GSTM1 and GSTT1 variants, on the outcome for 26 cyclophosphamide treated multiple myeloma patients. (diva-portal.org)
  • Cyclophosphamide (CTX), an alkylating agent, is a widely acknowledged anticancer chemotherapeutic agent used alone or in combination with other medicines for part of the mainstream therapy of several human malignancies [ 2 ]. (hindawi.com)
  • We find that wild-type and circadian mutant mice demonstrate striking differences in their response to the anticancer drug cyclophosphamide (CY). (pnas.org)
  • Cyclophosphamide is also converted to acrolein which is toxic to bladder epithelium and can lead to hemorrhagic cystitis. (ukessays.com)
  • We investigate the role of toll-like receptor (TLR4) on voiding dysfunction and inflammation in the cyclophosphamide (CYP)-induced mouse cystitis. (urotoday.com)
  • Recent studies suggest that janus-activated kinases-signal transducer and activator of transcription signaling pathways contribute to increased voiding frequency and referred pain of cyclophosphamide (CYP)-induced cystitis in rats. (frontiersin.org)
  • It has not been demonstrated that any single metabolite is responsible for either the therapeutic or toxic effects of cyclophosphamide. (nih.gov)
  • The conversion of cyclophosphamide to its alkylating metabolite(s) by microsomes obtained from male rat liver was characterized. (aacrjournals.org)
  • The next step, Dr. Chan said, is to reformulate cyclophosphamide so as to deliver only phosphoramide mustard, but effective delivery of the metabolite is hindered because of its rapid break down and elimination from the body. (cancernetwork.com)
  • It is a prodrug and the cytotoxic effects of cyclophosphamide depend on its metabolism by hepatic microsomes.Cyclophosphamide is converted to metabolite 4-hydroxycyclophosphamide (isomer of aldophosphamide) by oxidase enzymes in the liver .Phosphoramide mustard is most likely alkylating metabolites which alkylates under physiological condition which is directly cytotoxic to cells. (ukessays.com)
  • Each tablet for oral administration contains cyclophosphamide USP (calculated as anhydrous) 25 or 50 mg. (nih.gov)
  • Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models. (sigmaaldrich.com)
  • Cyclophosphamide (CFX) is a cytotoxic and immunosuppressive agent, used in systemic autoimmune diseases. (evidence.nhs.uk)
  • Cyclophosphamide is a potent anti-inflammatory and immunosuppressive cytostatic and cytotoxic drug used for such diverse medical problems as neoplasia, tissue transplantation, and inflammatory disease of uncertain cause. (annals.org)
  • Presently, we investigate the antitumor activity of the small-molecule angiogenesis inhibitor axitinib (AG-013736) and its potential for combination with metronomic cyclophosphamide. (aacrjournals.org)
  • However, in contrast to the substantial tumor regression that is ultimately induced by metronomic cyclophosphamide, the axitinib/cyclophosphamide combination was tumor growth static. (aacrjournals.org)
  • The antitumor effect of metronomic cyclophosphamide can be further improved by using gene therapy vectors to effect intratumoral expression of a cyclophosphamide-activating cytochrome P 450 enzyme as shown in preclinical studies ( 13 , 14 ). (aacrjournals.org)
  • Here, we assessed whether the delivery of IL-12 by gene therapy together with metronomic cyclophosphamide exerts antitumor effects in a murine model of colorectal carcinoma. (sigmaaldrich.com)
  • However, metronomic cyclophosphamide plus IL-12 gene therapy failed to increase the number of tumor-infiltrating T lymphocytes and, more importantly, to induce a specific antitumor immune response. (sigmaaldrich.com)
  • In this experiment, we studied the effects of the Dangguibuxue decoction (DBD) on the myocardial injury induced by cyclophosphamide in mice. (hindawi.com)
  • Microsomes from livers of female rats and mice metabolized cyclophosphamide with a V max of 0.66 and 9.69 µmoles/g/hr, respectively, and a K m of 0.67 and 0.68 m m , respectively. (aacrjournals.org)
  • To address the mechanistic aspects of the role of circadian clock in response to genotoxic stress induced by cancer therapy, we used three circadian mutant mouse models, Clock mutants, Bmal1 -/- mice, and Cry1 -/- Cry2 -/- knockout mice, and compared their in vivo drug response to a widely used chemotherapeutic drug cyclophosphamide (CY). (pnas.org)
  • Cyclophosphamide (CTX) prevents progression of nephritis and prolongs survival in (NZB × NZW)F 1 (B/W) mice and is used to treat humans with lupus nephritis. (jimmunol.org)
  • Unexpectedly, ICA69 null NOD mice were resistant to cyclophosphamide (CY)-accelerated diabetes. (jimmunol.org)
  • Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. (jci.org)
  • Cyclophosphamide (CTX) increases the antitumor effectiveness of adoptive immunotherapy in mice, and combined immunotherapy regimens are now used in some clinical trials. (jci.org)
  • In addition, cyclophosphamide induced abnormal peripheral blood FSH and E2 levels in mice. (spandidos-publications.com)
  • In this study, a water-soluble polysaccharide (MP) extracted from wild morels was evaluated for its effects on the gut microbiota of non-treated and cyclophosphamide (CP)-treated mice. (rsc.org)
  • Cyclophosphamide is also used to treat nephrotic syndrome (a disease that is caused by damage to the kidneys) in children whose disease has not improved, has gotten worse, or has come back after taking other medications or in children who experienced intolerable side effects with other medications. (medlineplus.gov)
  • In children whose disease fails to respond adequately to appropriate adrenocorticosteroid therapy or in whom the adrenocorticosteroid therapy produces or threatens to produce intolerable side effects, cyclophosphamide may induce a remission. (nih.gov)
  • Cyclophosphamide is also approved to treat "minimal change" nephrotic syndrome in children (a kidney disorder) when other treatments have produced intolerable side effects or have failed. (rxwiki.com)
  • Cyclophosphamide (CP) is an effective drug widely used for treating clinical cancer and non-malignant diseases. (mdpi.com)
  • For example, systemic lupus erythematosus with severe lupus nephritis may respond to pulsed cyclophosphamide. (wikipedia.org)
  • Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy. (biomedsearch.com)
  • Cyclophosphamide may induce autoimmune diabetes through a decrease in suppressor T cells and increase of proinflammatory T helper type 1 response in animal models. (medscape.com)